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Shared decisionmaking (SDM) is a recommended health communication approach
in mental health settings. Yet, implementation of SDM in psychiatric consultations
discussing medication management is challenging. Insufficient attention has been given
to examine the views of both clinicians and service users together about the experiences
of SDM in psychiatric medication management. The purpose of this paper is to examine
the views of service users, community psychiatric nurses, and psychiatrists about
enablers and barriers of SDM. A thematic analysis of 30 semi structured interviews with
service users, psychiatrists, and community psychiatric nurses, in a community mental
health team in the UK, was conducted. A service user advisory group was involved in
all phases of the research cycle, including data collection, analysis, and dissemination.
The results offer a detailed contextualized account of how medication decisions are
made. For psychiatrists and service user participants SDM is seen as a way of enhancing
service users’ engagement in and control over treatment decisions. While psychiatrists
value the transactional benefits of SDM, service user participants and psychiatric nurses
conceptualize SDM as a long-term endeavor embedded within therapeutic partnerships.
For service users these partnerships mitigate acknowledged problems of feeling unable
to be fully involved during times of crisis. This study identified a range of barriers and
facilitators to SDM concerning psychiatric medications from the lived experience of
service users and the professional experience of clinicians. Furthermore, it indicates new
potential intervention points to support SDM in psychiatric medication decisions.
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INTRODUCTION
Psychiatric medications are often considered to be the cornerstone of psychiatric care (1, 2). Yet,
many mental health service users do not choose to take medication consistently or at all (up
to 75%) despite the increased risk of relapse (1, 3–5). Overall, inconsistent use of psychiatric
medications may be a reflection of ineffective or lack of communication between psychiatrists
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and their patients regarding the harms and benefits of the
medications, the range of options and varying side effects,
and how psychiatric medications can facilitate recovery (6).
Inconsistent use of psychiatric medications is associated with
mental health services disengagement, frequent emergency
department visits, hospitalizations, and more-severe symptoms
over time (3, 7).
Shared decision making (SDM) is a recommended healthcare
communication practice, with the potential to improve
treatment decisions and health outcomes (8, 9). In an SDM
process the emphasis is on the patient as a person, taking
into account patient’s preferences, needs, beliefs, and concerns
about etiology and treatment, and incorporating patients’
experiential knowledge. SDM can also promote the person’s
involvement in their care, services engagement and treatment
adherence (8, 10). In mental health care, SDM has been
also associated with to promotion of self-determination,
self-directed care, and the personal recovery approach,
dominant across most health care systems in the Europe
and Anglophone countries (11, 12). SDM is viewed as an
ethical imperative across mental health systems globally
(13). In the UK, SDM has been embedded in policy and
practice guidelines for the last two decades and forms part
of statutory requirements and training among mental health
practitioners (14). SDM can lead to reduction in stigma and
increased involvement (15) and recovery outcomes, such as
improved quality of life and symptom severity (16) and patient
autonomy (17).
Although the promise of SDM in mental health has discussed
widely the evidence base remains weak and cultural barriers
to implementation appear paramount (18–20). Service users
often express desire to be involved in decisions and prefer
SDM to other models of patient participation (11, 21–23),
yet they often report lack of sufficient antipsychotics decision-
making involvement and knowledge about antipsychotics risks
and benefits (6, 24). Often concerns are expressed about
the competence of service users to be involved due to
issues of decisional capacity and insight, along with common
misconceptions that is it already happening, and that not all
patients want SDM (25–27).
Research into how SDM happens in meetings for psychiatric
medication management have found that psychiatrist often
employ persuasion in encounters with service users, and
concerns about adverse effects are often ignored (28, 29).
Clinicians, especially psychiatric care providers, often struggle
with using SDM in psychiatric medication decisions as SDM is
often perceived to involve risk for clinicians, such as liability
or making clinical errors (30). Yet, little research exists about
cultural and structural enablers and barriers in these settings.
In addition, the views of practitioners and service users taken
together are rarely reported yet offer important insights into areas
of divergence in views (18).
The purpose of the present qualitative study is to address these
knowledge gaps and explore cultural and structural barriers and
enables of SDM in psychiatric medication management from the




Participants were recruited from a community mental health
team (CMHT) that provided care to people with serious mental
illness (SMI) in the Eastern region of England, UK. Recruitment
was conducted via key workers in the CMHT and leaflets were
distributed in the local outpatient clinic.
Ethics
Ethical permission was obtained from an NHS research
ethics committee (#10-H0311-58) and all participants gave full
informed written consent. A broad inclusion criteria was used
to include all psychiatrists, mental health nursing staff, and adult
service users receiving services from the CMHT at the time of
study. People with a lack of capacity to give informed consent
and inadequate knowledge of English language were excluded
and diagnosis was not considered in the inclusion criteria. Service
user participants received £10 GBP as a token of thanks and to
reimburse for any travel expenses accrued. Staff did not receive
any reimbursement for participation.
Interviews and Data Collection: A
Co-Produced Effort
A project advisory group [consisting of three mental health
service users, a community psychiatric nurse (CPN), and one
carer] contributed to the development of the interview guide,
study design, data collection and analysis. The interview guides
for both practitioner and service user interview schedules
comprised of three sections: (1) general background questions
relevant to the topic (e.g., details of content of recent meetings)
(2) participants’ views and experiences of involving service
users in decision making about psychiatric medication (3)
discussion of recent memorable successful and unsuccessful
meetings where medication was reviewed (e.g., “what was it
about this meeting that particularly stood out for you as being
successful/unsuccessful?”). This style of questioning is known to
assist accessing more subtle views, less likely to be retrieved along
a more general line of questioning. Interviews lasted between 45
and 75min. Service user interviews were undertaken by the lead
researcher (EK), alongside co-researchers (service user members
of the advisory group). Clinician interviews were undertaken
by a sole interviewer (EK). All interviews were audio recorded
and transcribed using standard conventions, and subsequently
imported into the qualitative analysis software tool, N Vivo
(Version 10).
A Collaborative Data Analysis
We used an inductively oriented thematic analysis aiming
for a rich description of the entire data set and focusing
on meaning and lived experience of the phenomenon (31).
Including co-researchers in analysis supported this goal and
offered particular benefits (32). Best practice guidelines were
conformed to ensuring a transparent and deliberate process for
coproduced knowledge (32, 33).
A collaborative two stage approach was adopted. During
stage one the first author coded all interview transcripts and a
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TABLE 1 | Service user participant characteristics.
Participant
pseudonym
Age Gender Class/type of medication
currently prescribed
Named medication, if known Length of time taking psychiatric




Natasha 31 F Antidepressant Unknown Six months taking current medication CPN, GP
Holly 36 F Antidepressant Trepidone, 200mg Efexor (or known
as Venlafaxine), 300mg. Also
Gabapentin for pain
Taken psychiatric medication on and
off since 19 years old. (17 years
approx)
Clinical psychologist, GP
Mood stabilizer (for pain)
Carrie 38 F Antidepressant Fluoxetine, Mirtazapine, tryptophan,
Aripiprazole
Taken psychiatric medication on and
off for around 10 years. Most recent




Carl 28 M Antidepressant Unknown Just over a year GP, CPN, psychiatrist
Noel 47 M Antipsychotics Haloperidol, amitriptyline,
resperidone, depixol
On and off for 30 years. Psychiatrist, CPN, social
worker
Antidepressant
Ziggy 34 F Antidepressant Amitriptyline 2 months since new medication CPN, psychiatrist, GP
Linda 22 F Antidepressant Venlafaxine 2 months since new medication Psychiatrist, GP, CPN
Terry 31 M Atypical antipsychotic Closapine 400mg 2 years. Reduction in dose 9 months
ago
CPN, psychiatrist
David 23 M Unknown Unknown 4–5 months Psychiatrist, CPN
Lara 42 F Antidepressant Venlafaxine 2 weeks since new medication GP, psychiatrist
Peter 50 M Unknown Unknown Unknown GP
Andrew 49 M Antidepressant Unknown Since 2010 Psychiatrist, GP
Lizzy 54 F Antidepressant Venlafaxine, lithium (1,000mg) Venlafaxine: unknown. Lithium-6
years since dose changed. Total
10-15 years been taking lithium
CPN, psychiatrist
Mood stabilizer
Casey 28 F Antidepressant Fluoxetine, (60 milligrams) merotratine
(200 milligrams), sleeping tablet
Has been taking psychiatric
medication for ∼2 and a half years
GP, psychiatrist, nurse
Sleeping tablets
Rosie 24 F Antidepressant Venlafaxine, abilify (aripiprazole) Abilify changed recently but has been




sub sample were coded independently by the third author and
additional team member, followed by group discussion where
themes were continually and iteratively reviewed.
Stage two involved a co-production, collaborative analysis
of several transcripts from the service user interview data,
undertaken with all members of the project advisory group.
During this phase six group analysis meetings took place. These
meetings involved group coding of transcripts, discussions of
theme structure, and salience and divergence.
RESULTS
Our sample included 30 participants, of which 15 were service
users, 7 (out of a total of 8) psychiatrists working in the pathway,
and 8 (out of a total of 9) nurses. Background information for
participants are shown in Tables 1, 2. Service users aged from
22 to 54 (M = 36, SD = 10.18) and 60% (N = 9) were women.
The CMHT served ∼260 service users, with diverse needs and
SMI. The maximum length of stay within this service was 18
months. The majority of service user participants in this study
were prescribed antidepressants (n = 14, 93.3%), followed by
antipsychotics (n = 4, 26.6%), mood stabilizers (n = 2, 13.3%)
and sleep medication (n= 1, 6.6%). The majority of psychiatrists
and all the nurses interviewed had worked in the CMHT for over
6 months.
Three emergent superordinate themes were identified:
“Enacting SDM in service users–provider interactions,” “The
Therapeutic Relationship as an enabler of SDM,” and “structural
challenges to achieving SDM in practice.”
Enacting SDM in Service Users-Provider
Interactions
Four subordinate themes comprise the first broad domain which
encapsulates perceived key features of SDM for psychiatric
medication management comprising: (1) the importance of
SU ownership and control, (2) the dilemma of providing
information about adverse effects, (3) a meeting of experts—
valuing experiential knowledge, and (4) being ill as a barrier.
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TABLE 2 | Clinician participant characteristics.
Participant
identifier
Gender Job title and length of time working in the
CMHT pathway (at time of interview). Other
background information
Psychiatrist 1 M Consultant Psychiatrist for over 2 years in this
pathway. Qualified as a Consultant a number of
years ago and has worked in different mental health
teams locally.
Psychiatrist 2 M Consultant Psychiatrist in this pathway for ∼8
months. Previous role was also community based
psychiatry. Relatively newly qualified.
Psychiatrist 3 F Consultant Psychiatrist in this pathway for ∼1 year.
Qualified as a consultant a number of years ago and
has experience of many parts of MH services locally.
Psychiatrist 4 M Has acted as a Locum Consultant Psychiatrist in
the pathway for ∼2 months. Previously has worked
in many different MH teams and contexts
(acute/community) across different parts of the UK.
Psychiatrist 5 F Consultant Psychiatrist on specialist register.
Unknown length of time in pathway, but has worked
in the NHS for a number of years.
Psychiatrist 6 F Consultant psychiatrist in this pathway for 2 years.
Number of years experience in other parts of MH
service.
Psychiatrist 7 F Consultant psychiatrist in this pathway for ∼3
months. Newly qualified.
CPN 1 F Worked in pathway for ∼2 years. Extensive previous
experience of psychiatric nursing.
CPN 2 F Worked in pathway for over 2 years. Extensive
previous experience of community psychiatric
nursing.
CPN 3 F Team leader and community psychiatric nurse.
Worked in pathway for over 2 years and extensive
previous experience of psychiatric nursing.
CPN 4 F Worked in pathway for over 2 years. Extensive
previous experience of community psychiatric
nursing.
CPN5 M Worked in pathway for over 2 years. Extensive
previous experience of community psychiatric
nursing.
CPN 6 F Worked in pathway for ∼2 years. Extensive previous
experience of community psychiatric nursing.
CPN 7 F Worked in pathway for over 2 years. Extensive
previous experience of community psychiatric
nursing.
CPN 8 F Worked in pathway for over 2 years. Extensive
previous experience of community psychiatric
nursing.
The Importance of Service User Ownership and
Control
Service users, psychiatrists, and nurses viewed SDM in terms of
encouraging service users to have increased say over decisions
concerning medication, and promoting ownership and self-
determination in meetings concerning medication. All three
groups strived toward the service user achieving greater self-
management skills. Receiving a full explanation of options and
gaining detailed information about adverse effects was related
to feelings of increased control for service users and referred to
specifically by clinicians when describing memorable examples
of success. For service users, being able to understand the
information about the options were associated with feelings of
increased control. However, this was tapered by acknowledging
that during periods of crisis increased guidance and less
ownership over the decision is possible and the “sad truth you
just need someone to treat you” (Holly∗) (see section Being Ill as a
barrier). In these more difficult times, having information to take
away and revisit was associated with feeling more in control.
Casey: But I just think if I’d been given that information and going
through it yourself and having time to discuss it, you’re going to
understand. I just think you’d feel like you had more control and,
you know, that might reduce stigma, as well as you feeling you can
take control of what’s going on.
[∗ all names are pseudonyms]
CPN 4: I think she gained an understanding about how medication
could be useful and, how, you know, it had its place. But she was...
but she was taking control appropriately for when she took it. I felt,
yeah, she’s got it now, and that left me feeling reassured about her
coming off it this time.
For service users not feeling involved in discussion about options
in routine, while not in crises, was associated with feelings of
helplessness and lack of control.
Rosie: The last time that I saw her [the psychiatrist], my medication
was increased, and my mood was low but I didn’t really know, like
I wanted more options and I thought that it would have been better
if I had talked it through with her a bit more about increasing the
dose and instead she just increased the dose and that’ it.
The Dilemma of Providing Information About Adverse
Effects
All stakeholder groups stressed the importance of weighing
up information and ensuring service users are provided with
information about the potential adverse effects of medication
options, advocated in standard models of SDM (9). For most
service user participants there was a general concern about
associated adverse effects and many had previous negative
experiences of medication. Many participants referred to
not always receiving adequate information. Likewise, most
psychiatrists, while stressing the importance of disclosing
possible adverse effects, often referred to not doing so due to time
constraints and limiting the conversation about what side effects
might be important to them. Instead, psychiatrists preferred
referring service users to other sources of information, such
as leaflets. In addition, while psychiatrists did not think they
would deliberately withhold information on adverse effects, some
acknowledged that at times, limiting the discussion about adverse
effects and possible benefits of the medication was used as a way
(consciously or unconsciously) to encourage concordance and
avoid possible conflict (28).
Andrew: One thing is that you are never given enough information
about the side effects.
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Psychiatrist 1: And I’m probably not great about telling people
about possible longer term side effects about things and particularly
anti psychotics I suppose. I guess there are slightly peculiar
circumstances, so if someone’s psychotic and has lots of delusions
and is fairly wound up in them then a conversation about
medication can go a slightly odd way and tend to focus on symptoms
that might be otherwise quite secondary.
Psychiatrist 2: I think I’d usually say the commonest side effects
that other people have mentioned to me about medication, but I
usually tell them to look it up on the leaflet I provide, or the internet,
because there’s no way I can go through all the side effects and I don’t
know which of the side effects might be important to them.
A Meeting of Experts—Valuing Experiential
Knowledge
The vast majority of service users and CPN participants
mentioned the importance of service user’s experiential
knowledge for meaningful sharing of expertise in decisions. The
importance of both parties having a say, and equally contributing
to the conversation, is seen as integral to SDM. This may
be particularly important given acknowledged uncertainty of
helpfulness of medication options in this context.
Linda: Um, I think ideally it should be um, a collaboration between
the um, psychiatrist or prescribing doctor and the service user, so
there’s sort of the knowledge of the different types of medication on
the one side and then the SU knows how they are feeling, they know,
sort of whether they’ve got sort of patterns to their moods that sort
of certain types of drugs are more able to help with so it’s sort of a
feedback situation, with both of them contributing.
Psychiatrists also emphasized the importance of honesty and, at
times, disagreement was considered a success (and highlighted
this during descriptions of successful meetings). However,
CPNs and service users directly expressed the importance of
experiential knowledge and a shared dialogue. This aspect was
less explicit in the psychiatrists’ interviews who instead saw their
role as advisors for the evidence base of medication options,
which then may subsequently be weighed up by the service user
(see also section The importance of service user ownership and
control, above).
Being Ill as a Barrier
Challenges surrounding being ill or in crisis for service users
involvement in medication related decisions were discussed by
practitioners and service users. While research highlights that
many inpatients remain capable of participating meaningfully
during crisis [e.g., (34)] for service users, reinforcing information
and increased guidance become of greater importance during
crisis than at other times.
Carl: Um, I think if I’d been in a better place mentally at that time I
might have pulled up some questions, um but given how I was at the
time, um I don’t think I could have done much more because I was
looking to be informed by her [the psychiatrist] as much as anything
and, you know, that didn’t really happen at that point in time.
Lack of insight, or the SU not accepting that they are mentally ill,
was mentioned by both CPNs and psychiatrists as a key challenge
to SDM and was associated with changing how information is
presented and how medication conversations are constructed.
Problems when someone was acutely unwell being framed as
“lacking insight” by practitioners is an important issue in that a
person’s competence to participate is directly challenged by this
construction. Service users didn’t directly refer to problems of
lacking insight, but instead referred to functional problems of
poor concentration, memory problems, and distress hindering
being able to weigh up and process information aboutmedication
or be able express oneself clearly.
CPN 2: Particularly if someone’s very ill and their insight is very
poor, and you think, this person really does need to take medication,
they’re really unwell,. . . it’s important to find out, to support and
listen and advise and yet encourage concordance.
Psychiatrist 6: If they don’t necessarily see it as part of being ill, and
then it becomes quite difficult to involve people um on the same
level because you have to walk a fine line. . . . It’s not about giving the
wrong information but giving information that would lead people
to consider perhaps the options more carefully.
The Therapeutic Relationship as an
Enabler of SDM
Practitioners and service users alike emphasize the importance
of achieving a constructive therapeutic alliance and see this as
essential. Establishing trust and communicating honestly is seen
as an integral aspect of SDM by all participant groups (see
section Trust and honesty), yet different conceptualizations about
the longer-term, caring, and supportive aspects of relationships
emerge between stakeholders (see section Walking the Journey
Together and Continuity of Care).
Trust and Honesty
Service user participants were aware of the effort required by both
parties to establish a deeper relationship and understood that
SDM requires honesty on both sides. Several participants referred
to not just establishing a general rapport but rather an ongoing
effort in building mutual trust. Experiences that denigrated trust
were highlighted by service users as particularly damaging for
SDM. One participant referred to having to overcome previous
issues with trust and having to make a deliberate effort to trust
practitioners in order to embark on their own recovery process,
David: I have to do everything I can to allow myself to get better but
if it means I have to trust somebody that I don’t know, which is very,
very difficult for me to do, then so be it.
Carrie: I think the main thing is to be as honest as possible.....the
honesty and the trust I think as well, and you know you kind of
build up a relationship with somebody and you get to trust them.
When describing memorable positive meetings, psychiatrists
referred to establishing rapport and service users feeling able
to speak openly and honestly. Some psychiatrists acknowledge
that there are potentially differing agendas in conversations
concerning medication [and that conflict may emerge when
medication is deemed as the best course of action [see (28)].
In this context, service users feeling able to express their views
honestly is seen as a particular success. Conversely, issues of
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false compliance, or service users withholding information about
medication was often described as particularly concerning (but a
common reality) for many psychiatrists and CPNs.
Psychiatrist 3: I thought it was really good that she was able to talk
frankly about the pros and cons of the medication and she felt she
could say she needed this stuff. Yeah, good rapport, trust, a sense
that she could say what she really wanted. . . . [Because] I cannot
be absolutely sure that people are being absolutely honest with me
and would say. “I don’t want to take it.” I mean some of them are
going to say, “I got out of there . . .without losing face” and that’s
the problem, I don’t want people to go away and not take the drug
because they can’t face me, but they will, some of them.”
Walking the Journey Together and Continuity of Care
Establishing a long-term partnership and supporting people with
their personal recovery journeys was seen as integral to the
process of SDM for CPNs and SU participants. CPNs referred
to the importance of a supportive, long term relationship with
SUs. Care and empathy is emphasized reinforcing a deeper level
of connection as a way of facilitating a collaborative partnership.
Both groups saw this as a continued reflective process, of
being held accountable, pushing forward and having a belief in
one’s potential during more difficult times, and celebrating, and
reflecting on success over time. For SUs, meaningful involvement
was not seen as a series of isolated decisions, but instead, a
practitioner seeing and commenting on change over time was
connected to feelings of being known and cared about (see
Natasha, below).
CPN 2: So there’s a kind of walking the journey together, and
sometimes he’s pulling back a bit and I’m pushing forward and we
were at different paths pulling in different directions. That push -
pull stuff, [and] probably the success is about two people building
up a mutual respect and real affection for each other [And, for
example] thinking “I really care about you.”
Natasha: I don’t know, I think it’s because he [CPN] kept comparing
to how I was and how I am. So, you know; look how far you’ve come,
it was all just really positive, rather than “okay, you’ve taken it, well
done.” Yeah, it was real...and he was like; “well done, you know,
before you would have stopped and that would have been it but I’m
glad you have, you know, I’ really proud of you, you’ve done this,
you’re doing so well.”
Overall, psychiatrists didn’t emphasize longer term or caring
aspects of the therapeutic relationship. Only one psychiatrist (in
an example of a successful meeting) described how knowing the
person was an important feature of the meeting, and in general,
this was seen as not being central to the psychiatrist’s role (see
also section The changing role of the Psychiatrist, below).
Structural Challenges to Achieving SDM in
Practice
This theme reflects participants’ views surrounding the attitudes,
structures and cultural challenges of embedding SDM in
psychiatric medication management practice. Sub themes
include the move toward psychiatrists being seen as performing
an expert consultative role (The changing role of the Psychiatrist),
construction of distress as a medicalized phenomenon and
the associated labeling and stigmas as a barrier to SDM
(Medicalization of distress, Labeling, and stigma), and fear of
coercion as a barrier (Fear of coercion as a barrier to SDM).
The Changing Role of the Psychiatrist
Psychiatrists often discussed the changing role of the psychiatrist
toward that of being an expert advisor and performing a
consultative role in the medication management process. Five
psychiatrists referred to changing roles in recent years, with
family doctors (GPs) providing ongoing continuity of care. This
connected to the wider trend that longer term care for people
occur in the context of primary care and that psychiatrists often
only become involved as experts during crisis periods, or in
complex cases.
Psychiatrist 5: Compared to the past, where you would see a patient
and would continue to see them for a good length of time, you’d
build a relationship and you are overseeing the treatment for a
long period of time. From there to now it’s moving towardz the
GP being the center managing the patients and the consultant
psychiatrist providing a sort of consultative model... and there are
sort of pros and cons with either. But the current model is one
of where you don’t see the psychiatrist unless it’s um, extremely
complex, extremely risky.
Medicalization of Distress, Labeling, and Stigma
Concerns surrounding the dominant discourse of medical
understandings of mental health problems and distress emerged
as a barrier to collaborative decision making across all
three stakeholder groups. Within this, there were differences
in conceptualization across participant groups. Service users
referred to worries about labeling and stigma associated with
a psychiatric diagnosis, and as problematic for SDM. For
some participants, diagnosis related to feeling labeled and
prejudged impacting feelings of not being valued or listened to
in conversations about medication. Ziggy, when describing a
memorable negative meeting with his psychiatrist, refers to a
pretense of listening by the psychiatrist and feeling ignored: “And
there are some semblances of listening, but it’s not really going in
because in their mind they’ve already put a label on me.” For SUs
this theme is also connected to feelings of being spoken down to,
of not having a voice, and of a culture of doctor knows best. In
Natasha’s quote below, feelings of being attacked, looked down
upon and judged connected to being unable to contribute in a
conversation with her psychiatrist.
Natasha: I felt like I was being attacked and I don’t know, it was
like I was coming to them for help, it just felt like I was just being
attacked and judged and sort of looked down on and it just made
me feel really uncomfortable, upset. The fact that I was too scared
to say anything, it was, you know, just horrible, it made me feel
even worse.
Stigma was less directly referred to by psychiatrists and CPNs.
Instead, for some psychiatrists and CPNs the trend toward
an increased medicalization of distress and pathologization
of emotions is seen as an emergent and important problem
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for adopting a holistic approach and open discussions with
service users. This was seen as problematic for some CPNs and
psychiatrist participants who referred to feeling an increasing
pressure to prescribe connected to feeling that service users
expect a biomedical explanation and treatment for their mental
health problems. Here, passivity and “wanting to be led” was seen
as a challenge for SDM in mental health.
Psychiatrist 6: And I think there’s quite a push for society to see,
um, emotions as abnormal and therefore needing treatment. And I
think that’s certainly increased in the last couple of years, where I see
people who are under distress and find it very difficult to deal with
emotions that, um, that are probably, um, a combination of social
changes and, um, a kind of breakdown of society’s normal coping
strategies. So that’s my sense.
Fear of Coercion as A Barrier to SDM
The context of mental health services operating within a legal
framework and specifically the role of the Mental Health Act
(MHA) in removing choice and freedom in the decision making
process was acknowledged as a barrier to collaborative decision
making by psychiatrist and SU participants. Fear of coercion
and the legal context was seen as a particular barrier, hindering
honest dialogue, and preventing trust from being established.
In one interview a psychiatrist refers to a memorable recent
meeting with a service user and reflects that the service user
may be withholding information or feeling pressure to take
prescribed medication because of his previous experience “he
may be worried that people will cart him off to hospital if he stops
taking it.” Often a general fear of coercion was not necessarily
based on direct previous experience of being treated under the
MHA, but a general awareness of the legal context.
Terry: . . . so I thought to myself; if I get these things going on in
my brain, I won’t tell a psychiatrist because I don’t want to be
in hospital.
Interviewer: So that’s something you’ve learnt?
Terry: Try and be as honest as you can but hold back a little bit
because you don’t want to sort of end up in hospital when you look
different to society.
Interestingly, fear of coercion was not explicitly mentioned by
CPNs, perhaps suggestive of the differing role the CPN performs
to the psychiatrist in this pathway.
DISCUSSION
The findings of this study support broader conceptions of SDM as
a longer term process of trial and error, prioritizing honest open
dialogue, valuing experiential knowledge, positive risk taking,
and viewing psychiatric medication as only one possible choice
in a wider personal tool box approach (8, 30, 35).
These findings support other research exploring service users’
views of SDM and highlight the enabling role therapeutic
relationships play for SDM in mental health (11). Therapeutic
relationships and their connection to shared decision making
has been relatively unexplored. Research suggests that positive
outcomes of therapeutic relationships may be mediated by
impacts on increased involvement and SDM (36, 37).
Considerations of how power is enacted in mental
health services is critical (38). Insidious forms of power,
and perceived labeling, stigma and self-stigma impact SDM
directly via professional attitudes toward service users. Many
SDM professionals view people with SMI as incapable of
participating; and service users may internalize associated
stigmatizing attitudes, further hindering a person’s confidence to
express themselves and portray their preferences and values in
encounters with professionals (34).
Other forms of power, such as “aesulpian power” (or a power
to heal) suggest it is important to recognize that prescribers
perform important symbolic and functional roles (39). Yet,
for psychiatric medication management, this may lead to an
overly medicalized approach, with subsequent reduced emphasis
on personal meanings and wider psychological and social
understandings of medicines and threatening the ideal of a
meeting of experts and of experiential knowledge holding weight
encounters (40, 41). A clearer focus on shared risk taking as a
way of conceptualizing SDM for such encounters would allow for
a diffusion of power and authority and can lead to a meaningful
exploration of issues of accountability within the system along
with the context of the person’s broader life implications (30).
Implications for Practice
The findings suggest that future interventions to promote
SDM in practice need to take a multi-faceted approach,
including a focus on changing attitudes amongst mental health
practitioners, and empowering service users (12). Recent SDM
interventions have advocated for this broader organizational
change approach and show early promise, suggesting that
attitudes can be effectively changed to support the embedding
of SDM in practice (6, 8, 34). However, implementing SDM
in mental health settings requires particular attention to the
unique defining cultural features of this system. Interventions
with a particular emphasis on tackling the insidious effects
of labeling and stigma in psychiatry represent an important
avenue for future interventions and implementation of SDM
in mental health (34). The importance of co-production in the
development and implementation of interventions to embed
SDM in practice, may be particularly important in this regard
(20). In addition, promoting continuity of care and longer
term relationships is an important practical implication of the
findings. The findings suggest that the role of the CPN for
collaborative psychiatric medication management practices may
be particularly important. In theUK, an increasing fragmentation
of services, and increased emphasis on time-limited focused
provision leads to increasing concerns about the impact service
design has on health outcomes via reduced continuity of care,
both within and across different pathways (42, 43).
Strengths and Limitations of This Study
Presentation of themes across three stakeholder groups (CPNs,
service users and psychiatrists) allowed for discussion of
complexities and areas of convergence and divergence in
themes between stakeholder groups. Arguably incorporating
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multiple stakeholder groups also allows for a more sophisticated
construction. The co-produced elements of the research process,
and the inclusion of collaborative analysis phases enabled
through active involvement from the SU advisory group during
the analysis phases strengthened the credibility and quality of
the results. However, it may be that by highlighting differences
between groups, an artificial portrayal of homogeneity in views
within stakeholder groups is presented, portraying a crude
distinction that, for example, psychiatrists have one position on
this topic, and CPNs or service users another. This was not
the explicit intention and hopefully we were able to portray the
complexity of the themes and present both inter as well as intra
group differences in discourse.
The fact that participants were all recruited from CMHT in
one locality, should be considered in relation to relevance of
findings to other service users and practitioner populations. It is
also possible that selection bias was present in the recruitment
of service users participants within the pathway (this issue
doesn’t apply to interviews with professionals in that all but one
participated). It may be that those service users with existing good
relationships were approached for participation by gatekeepers
(mental health professionals in the CMHT). Also, people with
strong views or memorable experiences on the topic may have
been more interested in participating. As such, future research
should seek to recruit a more inclusive and varied service user
sample and involve a larger more representative sample.
Concluding Remarks
This is among the first studies to explore both practitioner
and service user perceptions of SDM for psychiatric medication
management. This study’s importance is also reflected in the
inclusion of CPN’s views (an under researched group) alongside
service user and psychiatrist views about SDM for medication
management is an important contribution. Currently there is
insufficient research examining wider cultural and structural
enablers and barriers for successful implementation in everyday
psychiatric practice. These results offer a detailed contextualized
account of how medication decisions are made and highlight
that SDM is a long-term endeavor embedded within therapeutic
partnerships. Stakeholder differences in views of SDM reflect
a complexity of relations which point to wider system and
cultural challenges at different stages of the SDM process. The
study provides actionable insights which may help improve SDM
practices and improve the quality of psychiatric care.
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